Here are five notable reactions to the chaos in France, which some see as part of a wider assault against a teetering ...

Rising crude oil prices do not necessarily end with just an increase in energy costs. They can ripple into prices through ...

GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to ...

Analysts are out in force on Netflix, with shares sliding after the streaming service posted its slowest revenue growth rate ...

Fresenius Medical Care, the world's leading provider of products and services for people with kidney disease, today announced the U.S.

This article is a personal summary of market conditions based on public information and is not an investment solicitation or advice.🧭 Today's brief conclusionThe market condition is 🟡 autonomous ...

A meta-analysis of 37 real-world lecanemab studies found ARIA in 15.1% of cases, with higher rates among APOE ε4 homozygotes and people with baseline microhemorrhages, but insufficient controlled ...

The FDA has approved Hibsago (bepirovirsen) as an add-on antisense oligonucleotide therapy to help noncirrhotic adults with chronic hepatitis B achieve functional cure.

In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...

The FDA approved Hibsago (bepirovirsen; GSK), the first antisense oligonucleotide for chronic hepatitis B, for use with a nucleos (t)ide analogue in adults without cirrhosis, the agency announced ...

Swiecicki, MD, of the University of Michigan Rogel Cancer Center, characterizes the safety and tolerability of subcutaneous ...

Seven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release Methylphenidat ...